Page 1 of 4

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

C	omplete if Known	
Application Number	10/578,216	
Filing Date	May 3, 2006	
First Named Inventor	Kevin R. Lynch et al.	
Art Unit	1626	
Examiner Name	Shawquia Young	-
Attorney Docket No.	198P000944USWO	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
/SY/		BRINKMANN, V., Pinschewer, D. D., Feng, L., and Chen, S. (2001) Transplantation 72, 764-769	
/SY/		MAKI, T., Gottschalk, R., and Monaco, A. P. (2002) Transplantation 74, 1684-1686	

	EXAMINER	/Shawquia Young/		Date Considered	01/02/2008	
			1			

Page 1 of #

STATEMENT BY APPLICANT

	Page 1 of
C	omplete if Known
Application Number	10/578,216
Filing Date	May 3, 2006
First Named Inventor	Kevin R. Lynch et al.
Art Unit	1626
Examiner Name	Shawquia Young
Attorney Docket No.	198P000944USWO

		U.S	. PATENT D	OCUMENTS	
Examiner Initials	Cite No.	Document Number Number-Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Т
		Country Code/Number/Kind Code				
/SY/		EP 1 553 091 A1	07-13-2005	Ikemoto et al.		Г
/SY/		WO 2006/001463 A1	01-05-2006	Habashita et al.	·	

EXAMINER	Date Considered
/Shawquia Young/	01/02/2008

*Examiner: initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 1 of 6

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

		Page 1 of t
.C		
Application Number	10/578,216	
Filing Date	May 3, 2006	
First Named Inventor	Kevin R. Lynch et al.	
Art Unit	1626	
Examiner Name	Shawquia Young	
Attorney Docket No.	198P000944USWO	

	U.S. PATENT DOCUMENTS				
Examiner Initials	Cite No.	Document Number Number-Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/SY/		US-6,875,757 B2	04-05-2005	Miller et al.	
/SY/		US-7,060,697 B2	06-13-2006	Marsilje et al.	
/SY/		US-7,064,217 B2	06-20-2006	Macdonald et al.	
/SY/		US-7,241,790 B2	07-10-2007	Lynch et al.	
/SY/		US-2004/0224941 A1	11-11-2004	Seko et al.	
/SY/		US-2005/0032744 A1	02-10-2005	Michaelis et al.	1
/SY/		US-2005/0023386 A1	02-24-2005	Nishi et al.	
/SY/		US-2005/0107447 A1	05-19-2005	Lynch et al.	
/SY/		US-2006/0135786 A1	06-22-2006	Saha et al.	
/SY/		US-2006/0223866 A1	10-05-2006	Evindar et al.	
/SY/		US-2007/0088002 A1	04-19-2007	Lynch et al.	
/SY/		US-2007-0191313 A1	08-16-2007	Beard et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code/Number/Kind Code				
· /SY/	8.	GB 950,388	02-26-1964	Smith Kline & French Laboratories		
/SY/		JP 2002-316985	10-31-2002	Takehide et al.	English Abstract provided	
ISYI		WO 99/35259	07-15-1999	Munroe et al.		
/SY/		WO 01/60819 A1	08-23-2001	Ueno et al.		Г
/SY/		WO 02/064616 A2	08-22-2002	Macdonald et al.		Γ
/SY/		WO 05/032465 A2	04-14-2005	Doherty et al.		Г

EXAMINER	/Shawquia Young/	Date Considered 01/02/2008
*Examiner: Initial	if citation considered, whether or not citation is	In conformance with MPEP 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Page 2 of 6

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

t al.
0

/SY/	WO 2006/020951 A1	02-23-2006	Saha et al.		
/SY/	WO 2006/063033 A2	06-15-2006	Lynch et al.		
/SY/	WO 2006/088944 A1	08-24-2006	Lynch et al.		
/SY/	WO 2007/085451 A2	08-02-2007	Albert et al.		
/SY/	WO 2007/086001 A2	08-02-2007	Bolli et al.	-	
/SY/	WO 2007/091396 A1	08-16-2007	Hasegawa et al.	-	
	-				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publicity and/or country where published.	
/SY/		International Search Report for PCT/US2004/036563 (2006) /SY/ 8/6/0)9
/SY/		BANDINI, Marco et al., "An Effective and Useful Synthesis of Enantiomerically Enriched Arylglycinols", Eur. J. Chem. 2001, 1937-1942	
/SY/		BEILSTEIN, XP-002380276 Date is unavailable /SY/ 8/6/09	
/SY/		BERTUS, Phillipe et al., "New and easy route to primary cyclopropylamines from nitriles", Chem Commun, 2001, 1792-1793	
/SY/		BRINKMANN, V. et al., V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., Foster, C. A., Zollinger, M., and Lynch, K. R. (2002) J Biol Chem 277, 21453-21457	
/SY/		BRINKMANN, V., Pinschewer, D. D., Feng, L., and Chen, S. (2001) Transplantation 72, 764-769	
/SY/		BURGER, Alfred et al., "1-Methyl-2-phenylcyclopropylamine", Journal of Medicine and Pharmaceutical Chemistry, Vol. 4, No. 3, 1961	
'/SY/		CHIBA, K., Yanagawa, Y., Masubuchi, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., and Hoshino, Y. (1998) J Immunol 160, 5037-5044	-
/SY/		CLAIR, T., Aoki, J., Koh, E., Bandle, R. W., Nam, S. W., Ptaszynska, M. M., Mills, G. B., Schiffmann, E., Liotta, L. A., and Stracke, M. L. (2003)	3

EXAMINER /Shawquia Young/	Date Considered 01/02/2008
	· ·

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 2 of 6

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for Form 1449/PTO

		_ rage 5 0 j 0
C	omplete if Known	
Application Number	10/578,216	
Filing Date	May 3, 2006	
First Named Inventor	Kevin R. Lynch et al.	
Art Unit	1626	
Examiner Name	Shawquia Young	
Attorney Docket No.	198P000944USWO	

		Cancer Res 63, 5446-5453	
ISYI		CLEMENS, J. J., Davis, M. D., Lynch, K. R., and Macdonald, T. L. (2003) Bioorg Med Chem Lett 13, 3401-3404	
/SY/		CLEMENS, Jeremy et al., "Synthesis of 4(5)-phenylimidazole-based analogs of sphingosine-1-phosphate and FTY720: Discovery of potent S1P ₁ receptor agonists", <i>Bioorganic & Medicinal Chemistry Letters</i> 15 (2005) 3568-3572	
ISYI	1	CROSIGNANI, Stefano et al., "4-Naphthyl-Substituted Bis(Oxazoline): a New Easily Recoverable and Efficient Chiral Ligand in Asymetric Catalysis of the Diels-Alder Reaction", <i>Tetrahedron</i> 54 (1998) 15721-15730	
/SY/		DAVIS, Michael D. et al., "Sphingosine 1-Phosphate Analogs as Receptor Antagonists", <i>The Journal of Biological Chemistry</i> , Vol. 280, No. 11, 2005, 9833-9841	
ISYI	i,	FORREST, M., Sun, S. Y., Hajdu, R., Bergstrom, J., Card, D., Doherty, G., Hale, J., Keohane, C., Meyers, C., Milligan, J., Mills, S., Nomura, N., Rosen, H., Rosenbach, M., Shei, G. J., Singer, II, Tian, M., West, S., White, V., Xie, J., Proia, R. L., and Mandala, S. (2004) <i>J Pharmacol Exp Ther</i> 309, 758-768	
/SY/		FOSS, Frank W. et al., "Synthesis and biological evaluation of γ- aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists", <i>Bioorganic & Medicinal Chemistry</i> 15, 2007, 663-677	
ISYI	- 13	FUJINO, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., and Li, X. K. (2003) J Pharmacol Exp Ther 305, 70-77	
/SY/		GRALER, M. H., and Goetzl, E. J. (2004) FASEB 18, 551-553	L
ISYI	-	HALE, Jeffrey J. et al., "Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720", Bioorganic & Medicinal Chemistry Letters 14, 2004, 3351-3355	
/SY/		HALE, J. J., Doherty, G., Toth, L., Mills, S. G., Hajdu, R., Ann Keohane,	L

EXAMINER	/Shawquia Young/	Date Considered	01/02/2008

Substitute for Form 1449/PTO
INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT

	Page 4 of 6
omplete if Known	
10/578,216	
May 3, 2006	
Kevin R. Lynch et al.	
1626	
Shawquia Young	
198P000944USWO	
	10/578,216 May 3, 2006 Kevin R. Lynch et al. 1626 Shawquia Young

ISYI		C., Rosenbach, M., Milligan, J., Shei, G. J., Chrebet, G., Bergstrom, J., Card, D., Forrest, M., Sun, S. Y., West, S., Xie, H., Nomura, N., Rosen, H., and Mandala, S. (2004) <i>Bioorg Med Chem Lett</i> 14, 3501-3505	
/SY/		HALE, J. J., Doherty, G., Toth, L., Li, Z., Mills, S. G., Hajdu, R., Ann Keohane, C., Rosenbach, M., Milligan, J., Shei, G. J., Chrebet, G., Bergstrom, J., Card, D., Rosen, H., and Mandala, S. (2004) <i>Bioorg Med</i> Chem Let 14, 3495-3499	
<i>I</i> SY/		HALE, Jeffrey J. et al., "A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzyl-3- carboxyazetidine Sphingosine-1-phophate-1 Receptor Agonists", J Med Chem, 2004, 47, 6662-6665	
/SY/		HANESSIAN, Stephen et al., "Constrained azacyclic analogues of the immunomodulatory agent FTY270 as molecular probes for sphingosine 1-phosphate receptors., Bioorganic & Medicinal Chemistry Letters 17, 2007, 491-494	
/SY/		HOSHINO, Y., Yanagawa, Y., Ohtsuki, M., Nakayama, S., Hashimoto, T., and Chiba, K. (1999) Transplant Proc 31, 1224-1226	
/SY/		IM, D. S., Heise, C. E., Ancellin, N., O'Dowd, B. F., Shei, G. J., Heavens, R. P., Rigby, M. R., Hla, T., Mandala, S., McAllister, G., George, S. R., and Lynch, K. R. (2000) <i>J Biol Chem</i> 275, 14281-14286	
/SY/		JONES, L., Schumm, J. S., and Tour, J. M. (1997) J Org Chem 62, 1388- 1410	
ISYI		KAISER, Carl et al., "2-Substituted Cyclopropylamines. I. Derivatives and Analogs of 2-Phenylcyclopropylamine", XP009032189, November 1962, 1243-1265	
/SY/	-	KAWASAKI, Ken-ichi et al., "Enantioselective Allylic Oxidation of Cycloalkenes by Using Cu(II)-Tris(oxazoline) Complex as a Catalyst", Tetrahedron, Vol. 53, No. 18, 1997, 6337-6350	
<i>I</i> SY <i>I</i>		KHAREL, Yugesh et al., "Sphingosine Kinase 2 Is Required for Modulation of Lymphocyte Traffic by FTY 720", <i>J Bio Chem</i> , Vol. 280, No. 44, November 4, 2005, 36865-36872	

EXAMINER	/Shawquia Young/	Date Considered	01/02/2008
The state of the s			

Page 5 of 6

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for Form 1449/PTO

		rage 3 of
Ī	C	omplete if Known
	Application Number	10/578,216
	Filing Date	May 3, 2006
	First Named Inventor	Kevin R. Lynch et al.
	Art Unit	1626
	Examiner Name	Shawquia Young
	Attorney Docket No.	198P000944USWO

KIMURA, T., Sato, K., Malchinkhuu, E., Tomura, H., Tamama, K., Kuwabara, A., Murakami, M., and Okajima, F. (2003) Arterioscler Thromb Vasc Biol 23, 1283-1288 KIUCHI, M., Adachi, K., Kohara, T., Minoguchi, M., Hanano, T., Aoki, Y., Mishina, T., Arita, M., Nakao, N., Ohtsuki, M., Hoshino, Y., Teshima, K., Chiba, K., Sasaki, S., and Fujita, T. (2000) J Med Chem 43, 2946-2961 KON, J., Sato, K., Watanabe, T., Tomura, H., Kuwabara, A., Kimura, T., Tamama, K., Ishizuka, T., Murata, N., Kanda, T., Kobayashi, I., Ohta, H., Ui, M., and Okajima, F. (1999) J Biol Chem 274, 23940-23947 LEE, M. J., Van Brocklyn, J. R., Thangada, S., Liu, C. H., Hand, A. R., Menzeleev, R., Spiegel, S., and Hla, T. (1998) Science 279, 1552-1555 KSY LEW, M. J., and Angus, J. A. (1995) Trends Pharmacol Sci 16, 328-337 LI, Zhen et al., "Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P ₁) Receptor Agonists with Exceptional Selectivity against S1P ₂ and S1P ₃ ", Journal of Medicinal Chemistry, Vol. 48, No. 20, October 6, 2005, 6199-6173 MAKI, T., Gottschalk, R., and Monaco, A. P. (2002) Transplantation 74, 1684-1686 MANDALA, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thomton, R., Shei, G. J., Card, D., Keohane, C., Rosenbach, M., Hale, J., Lynch, C. L., Rupprecht, K., Parsons, W., and Rosen, H. (2002) Science 296, 346-349. MATLOUBIAN, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., and Cyster, J. G. (2004) Nature 427, 355-360 SANCHEZ, T., Estrada-Hernandez, T., Paik, J. H., Wu, M. T., Venkataraman, K., Brinkmann, V., Claffey, K., and Hla, T. (2003) J Biol Chem 278, 47281-47290 SANNA, M. Germana et al., "Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P ₁ natagonist in vivo",			_
SY Y., Mishina, T., Arita, M., Nakao, N., Ohtsuki, M., Hoshino, Y., Teshima, K., Chiba, K., Sasaki, S., and Fujita, T. (2000) J Med Chem 43, 2946-2961 KON, J., Sato, K., Watanabe, T., Tomura, H., Kuwabara, A., Kimura, T., Tamama, K., Ishizuka, T., Murata, N., Kanda, T., Kobayashi, I., Ohta, H., Ui, M., and Okajima, F. (1999) J Biol Chem 274, 23940-23947 IEE, M. J., Van Brocklyn, J. R., Thangada, S., Liu, C. H., Hand, A. R., Menzeleev, R., Spiegel, S., and Hla, T. (1998) Science 279, 1552-1555 SY LEW, M. J., and Angus, J. A. (1995) Trends Pharmacol Sci 16, 328-337 LI, Zhen et al., "Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P), Receptor Agonists with Exceptional Selectivity against S1P, and S1P," Journal of Medicinal Chemistry, Vol. 48, No. 20, October 6, 2005, 6169-6173 SY MAKI, T., Gottschalk, R., and Monaco, A. P. (2002) Transplantation 74, 1684-1686 MANDALA, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thomton, R., Shei, G. J., Card, D., Keohane, C., Rosenbach, M., Hale, J., Lynch, C. L., Rupprecht, K., Parsons, W., and Rosen, H. (2002) Science 296, 346-349. MATLOUBIAN, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., and Cyster, J. G. (2004) Nature 427, 355-360 SANCHEZ, T., Estrada-Hernandez, T., Paik, J. H., Wu, M. T., Venkataraman, K., Brinkmann, V., Claffey, K., and Hla, T. (2003) J Biol Chem 278, 47281-47290 SANNA, M. Germana et al., "Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P, antagonist in vivo",	ISYI .	Kuwabara, A., Murakami, M., and Okajima, F. (2003) Arterioscler	
Tamama, K., Ishizuka, T., Murata, N., Kanda, T., Kobayashi, I., Ohta, H., Ui, M., and Okajima, F. (1999) J Biol Chem 274, 23940-23947 LEE, M. J., Van Brocklyn, J. R., Thangada, S., Liu, C. H., Hand, A. R., Menzeleev, R., Spiegel, S., and Hla, T. (1998) Science 279, 1552-1555 [SYl LEW, M. J., and Angus, J. A. (1995) Trends Pharmacol Sci 16, 328-337 LI, Zhen et al., "Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P ₁) Receptor Agonists with Exceptional Selectivity against S1P ₂ and S1P ₃ ", Journal of Medicinal Chemistry, Vol. 48, No. 20, October 6, 2005, 6169-6173 MAKI, T., Gottschalk, R., and Monaco, A. P. (2002) Transplantation 74, 1684-1686 MANDALA, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G. J., Card, D., Keohane, C., Rosenbach, M., Hale, J., Lynch, C. L., Rupprecht, K., Parsons, W., and Rosen, H. (2002) Science 296, 346-349. MATLOUBIAN, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., and Cyster, J. G. (2004) Nature 427, 355-360 SANCHEZ, T., Estrada-Hernandez, T., Paik, J. H., Wu, M. T., Venkataraman, K., Brinkmann, V., Claffey, K., and Hla, T. (2003) J Biol Chem 278, 47281-47290 SANNA, M. Germana et al., "Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P ₁ antagonist in vivo",	/SY/	Y., Mishina, T., Arita, M., Nakao, N., Ohtsuki, M., Hoshino, Y., Teshima,	
Menzeleev, R., Spiegel, S., and Hla, T. (1998) Science 279, 1552-1555 ISY LEW, M. J., and Angus, J. A. (1995) Trends Pharmacol Sci 16, 328-337 LL, Zhen et al., "Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P ₁) Receptor Agonists with Exceptional Selectivity against S1P ₂ and S1P ₃ ", Journal of Medicinal Chemistry, Vol. 48, No. 20, October 6, 2005, 6169-6173 MAKI, T., Gottschalk, R., and Monaco, A. P. (2002) Transplantation 74, 1684-1686 MANDALA, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thomton, R., Shei, G. J., Card, D., Keohane, C., Rosenbach, M., Hale, J., Lynch, C. L., Rupprecht, K., Parsons, W., and Rosen, H. (2002) Science 296, 346-349. MATLOUBIAN, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., and Cyster, J. G. (2004) Nature 427, 355-360 SANCHEZ, T., Estrada-Hernandez, T., Paik, J. H., Wu, M. T., Venkataraman, K., Brinkmann, V., Claffey, K., and Hla, T. (2003) J Biol Chem 278, 47281-47290 SANNA, M. Germana et al., "Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P ₁ antagonist in vivo",	ISYI	Tamama, K., Ishizuka, T., Murata, N., Kanda, T., Kobayashi, I., Ohta, H.,	
I.I. Zhen et al., "Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P ₁) Receptor Agonists with Exceptional Selectivity against S1P ₂ and S1P ₃ ", Journal of Medicinal Chemistry, Vol. 48, No. 20, October 6, 2005, 6169-6173	/SY/		
Syl Sphingosine-1-phosphate-1 (S1P ₁) Receptor Agonists with Exceptional Selectivity against S1P ₂ and S1P ₃ ", Journal of Medicinal Chemistry, Vol. 48, No. 20, October 6, 2005, 6169-6173	/SY/	LEW, M. J., and Angus, J. A. (1995) Trends Pharmacol Sci 16, 328-337	
SY 1684-1686 MANDALA, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G. J., Card, D., Keohane, C., Rosenbach, M., Hale, J., Lynch, C. L., Rupprecht, K., Parsons, W., and Rosen, H. (2002) Science 296, 346-349. MATLOUBIAN, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., and Cyster, J. G. (2004) Nature 427, 355-360 SANCHEZ, T., Estrada-Hernandez, T., Paik, J. H., Wu, M. T., Venkataraman, K., Brinkmann, V., Claffey, K., and Hla, T. (2003) J Biol Chem 278, 47281-47290 SANNA, M. Germana et al., "Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral SIP, antagonist in vivo",	/SY/	Sphingosine-1-phosphate-1 (S1P ₁) Receptor Agonists with Exceptional Selectivity against S1P ₂ and S1P ₃ ", <i>Journal of Medicinal Chemistry</i> , Vol.	
Milligan, J., Thomton, R., Shei, G. J., Card, D., Keohane, C., Rosenbach, M., Hale, J., Lynch, C. L., Rupprecht, K., Parsons, W., and Rosen, H. (2002) Science 296, 346-349. MATLOUBIAN, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., and Cyster, J. G. (2004) Nature 427, 355-360 SANCHEZ, T., Estrada-Hernandez, T., Paik, J. H., Wu, M. T., Venkataraman, K., Brinkmann, V., Claffey, K., and Hla, T. (2003) J Biol Chem 278, 47281-47290 SANNA, M. Germana et al., "Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P ₁ antagonist in vivo",	/SY/	MAKI, T., Gottschalk, R., and Monaco, A. P. (2002) Transplantation 74,	
Brinkmann, V., Allende, M. L., Proia, R. L., and Cyster, J. G. (2004) Nature 427, 355-360 SANCHEZ, T., Estrada-Hernandez, T., Paik, J. H., Wu, M. T., Venkataraman, K., Brinkmann, V., Claffey, K., and Hla, T. (2003) J Biol Chem 278, 47281-47290 SANNA, M. Germana et al., "Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral SIP, antagonist in vivo",	/SY/	Milligan, J., Thornton, R., Shei, G. J., Card, D., Keohane, C., Rosenbach, M., Hale, J., Lynch, C. L., Rupprecht, K., Parsons, W., and Rosen, H.	
Venkataraman, K., Brinkmann, V., Claffey, K., and Hla, T. (2003) J Biol Chem 278, 47281-47290 SANNA, M. Germana et al., "Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo",	/SY/	Brinkmann, V., Allende, M. L., Proia, R. L., and Cyster, J. G. (2004)	
restoration of lymphocyte egress by a chiral S1P ₁ antagonist in vivo",	ISYI	Venkataraman, K., Brinkmann, V., Claffey, K., and Hla, T. (2003) J Biol	
Nature Chemical Biology, Vol. 2, August 2006, 434-441	/SY/		
/SY/ SANNA, M. G., Liao, J., Jo, E., Alfonso, C., Ahn, M. Y., Peterson, M. S.,	ISYI		Γ

EXAMINER /Shawquia Young/	Date Considered	01/02/2008
---------------------------	-----------------	------------

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449/PTO

INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT

Cor
Application Number
Filing Date
First Named Inventor
Art Unit

	I uge 0 (ŋυ		
C	omplete if Known			
Application Number	10/578,216			
Filing Date	May 3, 2006			
First Named Inventor	Kevin R. Lynch et al.			
Art Unit	1626	_		
Examiner Name	Shawquia Young			
Attorney Docket No.	198P000944USWO			

/SY/	Webb, B., Lefebvre, S., Chun, J., Gray, N., and Rosen, H. (2004) J Biol Chem 279, 13839-13848	×
/SY/	SUZUKI, S., Enosawa, S., Kakefuda, T., Li, X. K., Mitsusada, M., Takahara, S., and Amemiya, H. (1996) Transpl Immunol 4, 252-255	
/SY/	VAN BROCKLYN, J. R., Tu, Z., Edsall, L. C., Schmidt, R. R., and Spiegel, S. (1999) <i>J Biol Chem</i> 274 , 4626-4632	
ISYI	VOGLER, Rüdiger et al., "Sphingosine-1-Phosphate and Its Paradoxical Effects on Critical Parameters of Cutaneous Wound Healing", <i>The Journal of Investigative Dermatology</i> , Vol. 48, No. 20, 2005, 6169-6173	
/SY/	XIE, J. H., Nomura, N., Koprak, S. L., Quackenbush, E. J., Forrest, M. J., and Rosen, H. (2003) <i>J Immunol</i> 170, 3662-3670	
/SY/	YANAGAWA, Y., Hoshino, Y., and Chiba, K. (2000) Int J Immunopharmacol 22, 597-602	
/SY/	YANAGAWA, Y., Hoshino, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., Sugahara, K., and Chiba, K. (1999) <i>Transplant Proc</i> 31, 1227-1229	
/SY/	YANG, Z., Chen, M., Fialkow, L. B., Ellett, J. D., Wu, R., Brinkmann, V., Nadler, J. L., and Lynch, K. R. (2003) Clin Immunol 107, 30-35	
/SY/	ZHANG, T., Nanney, L. B., Luongo, C., Lamps, L., Heppner, K. J., DuBois, R. N., and Beauchamp, R. D. (1997) Cancer Res 57, 169-175	
ISYI	ZHANG, Y. H. et al., "Sphingosine-1-Phosphate Via Activation of a G-Protein-Coupled Receptor(s) Enhances the Excitability of Rat Sensory Neurons", J Neurophysiol 96, 2006, 1042-1052	
/SY/	ZHANG, Y. H. et al., "Intracellular sphingosine 1-phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neurons", <i>J Physiol</i> 575.1, 2006, 101-113	

EXAMINER	/Shawquia Young/		Date Considered 01/02/2008				
1							
AT THE RESERVE OF THE PARTY OF							

Operation (1997)

U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no pensors are required to respond to a collection of information unless closations a valid OMS court of un

01/02/2008

200 inder the Paperwork Reduction Act of 1995, no p Substitute for form 1449A/PTO

Sheet

Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

/Shawquia Young/

TEMENT BY APPLICANT

(Use as many sheets as necessary)

of

Complete if Known					
Application Number	10/578.216				
Filing Date	05/03/06				
First Named Inventor	Kevin R. Lynch				
Art Unit	Unknown				
Examiner Name	Unknown				
Attorney Docket Number	00944-03				

U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (Flanows)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
ISYI	1	us- 6,069,251	05/30/2000	Thurkauf, et al.	Entire Document			
SY/ SY/	2	us- 5,405,988	04/11/1995	Klar, et al.	Entire Document			
SY/	3	us- 4,939,130	07/03/1990	Jaeggi, et al.	Entire Document			
	T	US-						
	Т	US-						
	—	US-						
		US-						
	_	US-						
		US-						
	—	US-						
	+-	US-						
	_	US-						
	_	US-						
	1	US-						
	T	US-						
	1	US-						
	<u> </u>	U\$-		†				
	1	US-						

	FOREIGN PATENT DOCUMENTS										
Examiner Initials*				Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7°				
/SY/	4	wo	2004/010987	A2	07/23/2003	Brinkmann, et al.	Entire Document				
/SY/	5	wo	02/076995	A2	10/03/2002	Albert, et al.	Entire Document				
ISYI	6	wo	2004/103306	A2	12/02/2004	Pan, et al.	Entire Document				
/SY/	7	wo	2004/096752	Al	11/11/2004	Hinterding, et al.	Entire Document				
/SY/	8	wo	2004/028521	A2	04/08/2004	Foster, et al.	Entire Document				

EXAMPLES hitsi if returnous consistents, whether or not citation is in continuance with IMPEP 8(8). Draw in the through distation in the continuance and not considered healthcopy of this term with most communication to applicate. If application, single-station designation number (options), 2 see Micros Codes of USPTO Patent Documents at lever, signation or MPEP 9(1) 64. 3 Einst Office that issued the document, by the healthcoments, the indication of the year of the region of the Empower must precede the sensit number of the patent document \$57.3, 1 and \$7.3, 1 and

The Residence of Information is required by 37 CFR 147 and 18. The Information is required to obtain or retain a boreful by the public which is to fit (and by the DEF) process) appeticables. Confederably is a person by 38 U.S.C. 22 and 37 CFR 14. The collection is estimated to table 2 houses to complete, and the process of the process

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

Unde	er the Paperwork Reduction Act of 1995.	no per	sons are required to re	u.S. Patent and 1 rader spond to a collection of informat	ion unless it contains a valid OMB control number.	
	stitute for form 1449A/PTO			Complete If Known		
300	Baldie la loilli 1443/41 10			Application Number	10/578,216	
11	NFORMATION DISC	CI C	SURE	Filing Date	05/03/06	
	TATEMENT BY AF			First Named Inventor	Kevin R. Lynch	
•	MAILMENT DI AI		IOAIII	Art Unit	Unknown	
	(Use as many sheets as nec	esserv	1	Examiner Name	Unknown	
Sheet		of	3	Attorney Docket Number	00944-03	

			U. S. PATENT (OCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	_	Number-Kind Code ^{2 (Flanown)}			
		US-			
		US-			
	T-	US-			
		US-			
	<u> </u>	US-			
	1	US-			
	t	US-			
		US-			
		US-			
	т	US-			
	1	US-			
-	T	US-			
	1	US-			
		US-			
	T	US-			
		US-			
		US-			
	1	US-			

	FOREIGN PATENT DOCUMENTS									
Examiner Initials* Cite Foreign Patent Document No.* Country Code**Number**Kind Code*(If known)			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	τ°				
/SY/	9	wo	2004/024673	Al	03/25/2004	Buehlmayer, et al.	Entire Document			
/SY/	10	wo	2004/017917	A2	03/04/2004	Evans, et al.	Entire Document			
/SY/	11	wo	2004/103279	A2	12/02/2004	Colandrea, et al.	Entire Document			
/SY/	12	wo	03/061567	A2	07/31/2003	Doherty, et al.	Entire Document			
/SY/	13	wo	03/059880	Αl	07/24/2003	Sankyo Company, Ltd.	Entire Document			

Examiner Signature	/Shawquia Young/	Date Considered	01/02/2008
$\overline{}$		In age to the though all	tion if and in conformance and not

"EXAMPLE: Initial I interesco conclosed, whether or not clation is in conformance with MEPE 508. Clare vine brough distinct in all or conformance and not considered betake copy of this form which not communication to applicant." A pipectrain sulings citation designation number (optional), 2 see Micha Codes of USPTO Petent Documents, a wexassistation or WFEP 901.04. 2 Faire Office that issued the document, by the two-letter code (WIPO Standard ST 3), 4 For Lagranese parties document, by the indication of the year of the regine of the Emperor must proced the scenal number of the partiest document with the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. * Applicant is to place a Check mark here if English language Transistion is station.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or relatin bounds by the pack which is to fit feet of by the USFTO is process) an application. Confidentiality is governed and 1.98 CFR 2 and 2 CFR 1.47. The collection is estimated to take 2 hours to complete, but the process of the confidential transport of the USFTO. Time will vary deponding upon the individual case. Any common the amount of the pay require to complete this form and/or suggestions for reducing this trutter, should be sent to be CFR official or officer, U.S. Peterni and Trademant Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 2231-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND OT Commissioner for Petertine, P.O. 80x 1450, Alexandria, VA 2231-1450.

PTO/SB/08a (08-03)

01/02/2008

Approved for use through 07/31/2008, OMB 0651-0031

Substituto	ubstitute for form 1449A/PTO			Complete if Known		
0000000	io om man			Application Number	10/578.216	
INFO	DRMATION DISC	CLOS	URE	Filing Date	05/03/06	
	TEMENT BY AF			First Named Inventor	Kevin R. Lynch	
SIA	IENLINI DI AI	LIC	~! ! !	Art Unit	Unknown	
	(Use as many sheets as nec	nessand		Examiner Name	Unknown	
heet	:3	of	:3	Attorney Docket Number	00944-03	

	_		U. S. PATENT I	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (Flanown)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	t^{-}	US-			
	\vdash	US-			
	 	US-			
	 	US-			
	_	US-			
	 	US-			
	-	US-			-,-
	 	US-			
		US-			
	\vdash	US-			
	\vdash	US-			
		US-			
	T	US-			
	T	US-			
	\top	US-			
	1	US-			_
		US-			
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner initials*	Cite No.	Foreign Patent Document Country Code ³ -Number ⁴ -Yund Code ³ (# known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76	
/SY/	14	WO 02/0	92068	A 1	11/21/2002	Ono Pharmaceutical	Entire Document	L
								F
								+

Separate PEXAMER: Initial if reference correlated, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of the form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Occupant, and the conformance of the conformance and not considered, including the conformance and not considered conformance and not con

Examiner Signature

/Shawquia Young/

This collection of internation is required by 37 FFR 187 and 188. The information is required to plate in or metal a boreful by the paties which is for file (and by the paties of the p